SPOTLIGHT: ImaRx switches development focus

It's the season for strategic alternatives in biotechnology. This time it's ImaRx Therapeutics' turn, which has changed its focus from developing its SonoLysis program--proprietary microbubbles and ultrasound to treat ischemic stroke--to concentrating on the commercial opportunities for urokinase product sales. In a release, the company explained that they would have needed to find new financing this year if they had stayed focused on the clinical development of SonoLysis. Now those charges could be borne by a "third party" drawn in by the strategic review. Release

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.